• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·EMMESSA.BO
Share

Emmessar Biotech & Nutrition Limited Stocks

₹ 22.32Last Updated 26.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

₹ 1.11M

₹ 22.32
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Emmessar Biotech & Nutrition Ltd. specializes in the creation and distribution of health-related and dietary products. The company's operations are segmented into Healthcare, Fine Chemicals, and income generated from leased property. Its product offerings encompass solutions for dermatological care, general wellness, musculoskeletal support, pain management, and sexual health. Established by Mathurakavi Srinivas Raghavan Ayyangar on March 17, 1992, the firm is headquartered in Mumbai, India.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.10.2026 13:34

Outflows from tech stocks, a rocky start, and market distortions: Why Anthropic’s IPO Is Risky

27.10.2026 13:07

Hot Dogs vs. Squid. Will Netflix Save Its Business With a New Strategy?

27.10.2026 12:01

Top Stories This Morning: Intel to Acquire Quantum Startup, DoorDash in Talks for a $17 Billion Deal

27.10.2026 11:18

Stocks in South Korea and Japan surged on news of Anthropic's IPO. Is it time to buy?

27.10.2026 09:01

Anthropic's need for capital is growing. Will it receive an investment rating?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026